GlucoTrack (GCTK)
NASDAQ:GCTK
Want to see GCTK full AI Analyst Report?
GCTK Stock Chart & Stats
$1.93
-$0.03(-1.53%)
At close: 4:00 PM EST
$1.93
-$0.03(-1.53%)
Day’s Range― - ―
52-Week Range$0.62 - $15.90
Previous Close$0.14
Volume19.82K
Average Volume (3M)2.54M
Market Cap
$1.45M
Enterprise Value-$6.90M
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$33.00K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.98
Shares Outstanding1,944,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.23
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-4.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit164.20
Enterprise Value/Ebitda0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Intellectual PropertyIssuance of three U.S. patents covers core sensor chemistry, lead design and low-power electronics, creating a durable IP moat. This strengthens barriers to entry, increases bargaining power with partners, and supports long-term commercialization and licensing opportunities if clinical rollout succeeds.
Clinical & Regulatory ProgressCompleted first-in-human and feasibility trials with strong performance metrics and no serious adverse events, and is preparing an FDA IDE. These milestones materially de-risk product development, enable U.S. pivotal testing, and underpin a multi-year pathway toward market access and reimbursement if trials continue to validate performance.
Low LeverageMinimal recorded debt reduces near-term solvency risk and interest burden, preserving operational flexibility as clinical programs continue. Low leverage is a durable balance-sheet strength versus peers with high debt, though it does not eliminate funding needs tied to cash burn.
Bears Say
Lack Of RevenueThe company remains essentially pre-revenue with persistent negative gross profit, indicating it has not achieved commercialization. Over time this increases execution risk: until meaningful revenue is generated, long-term viability depends on successful trials, regulatory approval, and adoption by payers and clinicians.
High Cash BurnSubstantial and persistent negative operating and free cash flow (about -$15M TTM) creates ongoing funding pressure. Durable implications include reliance on external financing, potential dilution, and constrained ability to scale commercial preparations without fresh capital, which can slow product launch timelines.
Dilution & Financing RiskRecent shareholder approvals and executed debt-for-equity exchanges expand the company's capital flexibility but also signal meaningful dilution risk. Repeated equity issuance to fund operations can erode per-share value, reduce existing holders' upside, and pressure management to prioritize financing over long-term value creation.
GlucoTrack News
GCTK FAQ
What was GlucoTrack’s price range in the past 12 months?
GlucoTrack lowest stock price was $0.62 and its highest was $15.90 in the past 12 months.
What is GlucoTrack’s market cap?
GlucoTrack’s market cap is $1.45M.
When is GlucoTrack’s upcoming earnings report date?
GlucoTrack’s upcoming earnings report date is May 20, 2026 which is in 30 days.
How were GlucoTrack’s earnings last quarter?
GlucoTrack released its earnings results on Mar 30, 2026. The company reported -$3.984 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.984.
Is GlucoTrack overvalued?
According to Wall Street analysts GlucoTrack’s price is currently Overvalued.
Does GlucoTrack pay dividends?
GlucoTrack does not currently pay dividends.
What is GlucoTrack’s EPS estimate?
GlucoTrack’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GlucoTrack have?
GlucoTrack has 1,944,279 shares outstanding.
What happened to GlucoTrack’s price movement after its last earnings report?
GlucoTrack reported an EPS of -$3.984 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -14.021%.
Which hedge fund is a major shareholder of GlucoTrack?
Currently, no hedge funds are holding shares in GCTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GlucoTrack
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.